anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses an asthma-relieving medicament. In the medicament, sinapine is used for preventing asthma. The medicament is prepared into asthma-relieving aerosol preferentially, and in the asthma-relieving aerosol, sinapine thiocyanate solution is taken as a raw material, wherein a ratio of the weight of sinapine thiocyanate to the volume of distilled water is (1-2):(10-20); and the solution is filled into an aerosol container, a propellant is pressed, and the container is sealed to ensure that the solution forms the aerosol. The asthma is treated in an atomizing administration mode, so the asthma-relieving medicament has the advantages of quick response, high bioavailability, high adaptation of patients and capability of saving dosage and is convenient to use. In addition, due to the adoption of the atomizing administration mode, the first-pass effect and the stimulation effect of medicaments on gastrointestinal tracts can be prevented. In the technology of the asthma-relieving medicament, the sinapine is separated from natural plants and purified, and animal experiments prove that the sinapine has the obvious effects of relaxing bronchogenic smooth muscles and obvious and lasting effect of resisting the spasm of the smooth muscles, and high safety and does not have toxic or side effect, and the spasm of the smooth muscles is difficult to relapse. The asthma-relieving medicament has the obvious characteristics of treating externally intracorporal diseases and combining prevention and treatment along with green treatment, economy, practicality and the like.
Prospective audit with feedback during infectious diseases ward rounds (IDWR) is a common antimicrobial stewardship (AMS) practice on the Paediatric Intensive Care Unit (PICU). These interdisciplinary meetings rely on the quality of handover, with high risk of omission of information. We developed an electronic platform integrating infection-related patient data (COSARAPed). In the mixed PICU of a Belgian tertiary hospital we conducted an observational prospective cohort study comparing patient handovers during IDWRs using the COSARAPed-platform to those with access only to conventional resources. The quality of handover was investigated directly by assessment if the narrative was in accordance with Situation-Background-Assessment-Recommendation principles and if adequate demonstration of diagnostic information occurred, and also indirectly by registration if this was only achieved after intervention by the non-presenting AMS team members. We also recorded all AMS-recommendations. During a 6-month study period, 24 IDWRs and 82 patient presentations were assessed. We could only find a statistically significant advantage in favor of COSARAPed by indirect evaluation. We registered 92 AMS-recommendations, mainly resulting in reduced antibiotic pressure. We concluded that the IDWR is an appropriate platform for AMS on the PICU and that the utilisation of COSARAPed may enhance the quality of patient handover.
PURPOSE: A humanized anti-EMAPII anti body is provided to have identical or enhance antigen combining ability and to show reduced immunogenicity and increased half life. CONSTITUTION: A humanized anti-EMAPII(endotherial monocyte activating polypeptide II) anti body comprises a light chain variable domain having amino acid sequence described in the sequence number 12(SEQ ID NO:12)-18 and a heavy chain variable domain having amino acid sequence described in the sequence number 20-26. The humanized anti-EMAPII additionally includes human lgG1 originated constant domain. A pharmaceutical composition for preventing or treating TNF- A mediated disorder or Alzheimer disease includes the humanized anti-EMAPII. An EMAPII quantitative kit includes the humanized anti-EMAPII antibody. A recombinant vector comprises nucleic acid molecule which codes the light chain variable domain having the amino acid sequence described in the sequence number 12-18, and the nucleic acid molecule which codes the heavy chain variable domain having the amino acid sequence described in the sequence number 20-26.
### Pediatrics

PHENERGAN Injection should not be used in pediatric patients less than 2 years of age because of the potential for fatal respiratory depression. Postmarketing cases of respiratory depression, including fatalities, have been reported with use of promethazine in pediatric patients less than 2 years of age. A wide range of weight-based doses of PHENERGAN Injection have resulted in respiratory depression in these patients.  
Caution should be exercised when administering PHENERGAN Injection to pediatric patients 2 years of age and older. It is recommended that the lowest effective dose of PHENERGAN Injection be used in pediatric patients 2 years of age and older. Avoid concomitant administration of other drugs with respiratory depressant effects because of an association with respiratory depression, and sometimes death, in pediatric patients.

### Other

Because of the risk of potentially fatal respiratory depression, use of PHENERGAN Injection in patients with compromised respiratory function or patients at risk for respiratory failure (e.g. COPD, sleep apnea) should be avoided.
In a new procedure for producing gelatin capsules which are resistant to gastric juice, the capsule-mass or the preformed capsules is or are treated with a soln. of phthalaldehydic acid (Ia), isopthalaldehydic acid (Ib) or terephthalaldehydic acid (Ic). The aldehyde group of (Ia-c) binds with the gelatin, and the carboxylic acid group prevents dissolution at the acidic gastric pH while giving controlled dissolution in the neutral medium of the intestine. Treatment with (Ia-c) can be effected at any stage in the prodn. of hand or soft gelatin capsules. Particularly preferred is the application of a soln. of (Ia-c) to the pre-formed gelatin capsules, before or after drying. Used for rendering gelatin capsules resistant to gastric juice in order to protect medicaments from gastric hydrochloric acid and/or to protect the gastric mucosa from the adverse effects of medicaments.
Perceived temperature (PT), which encompasses meteorological factors such as wind speed, cloud cover, and humidity, reflects the actual effect of temperature on the human body. However, limited data exist on the health implications of prolonged exposure to low temperatures during winter in individuals with chronic kidney disease (CKD). We investigated the association between winter PT and long-term outcomes among CKD patients. A total of 32,870 CKD patients from three tertiary hospitals in Seoul were enrolled in this retrospective study (2001-2018). PT was calculated using Staiger's equation, integrating temperature data from 29 automated weather stations across Seoul, along with dew point temperature, wind velocity, and cloud cover data. Kriging interpolation was utilized to estimate PT values at the patients' locations. Overall mortality and major adverse cardiovascular events (MACEs) were assessed using a time-varying Cox proportional hazards model. Additionally, the Cox regression model evaluated PT corresponding to temperature thresholds for cold surge watches or warnings. Over a median follow-up of 6.14 ± 3.96 years, 6147 deaths (18.7%) were recorded. We found that as the average or minimum PT and Ta decreased by 1 °C, the risk of overall mortality significantly increased. In multivariable analyses, the hazard ratio (HR) for the average PT was 1.049 (95% confidence interval [CI] 1.028-1.071), and that for the minimum PT was 1.038 (CI 1.027-1.052). Furthermore, a cold surge warning at a PT of -25.63 °C indicated an HR of 1.837 (CI 1.764-1.914) and a C-index of 0.792. The increased risk of mortality was more pronounced in patients with low or middle socioeconomic statuses. For MACEs, lower average and minimum PT and Ta were associated with an increased risk, following a similar trend to overall mortality, although not all results reached statistical significance. These findings emphasize the importance of targeted public health policies to mitigate risks among vulnerable CKD patients.
Twenty subjects with abnormal esophageal motility (5 subjects each with achalasia, nutcracker esophagus, scleroderma, diffuse esophageal spasm or hypertensive LES) previously referred for clinical esophageal motility testing will be contacted. These twenty subjects must have previously undergone esophageal manometry testing using the standard clinical protocol at the University of Utah motility with solid state manometry catheters. After obtaining informed consent, these twenty subjects will undergo the esophageal manometry using air-filled balloon catheters per the standard clinical protocol. Following the repeat procedure a short one-page questionnaire will be completed by the subject and the motility nurse.

Five subjects with the diagnosis of incontinence previously referred for clinical anorectal motility testing will be contacted. These five subjects must have previously undergone anorectal manometry using the standard clinical protocol for an anorectal manometry study with water perfused anorectal manometry catheters. After obtaining informed consent, these five subjects will undergo the anorectal manometry using air-filled balloon catheters per the standard clinical protocol. Following the repeat procedure a short one-page questionnaire will be completed by the subject and the motility nurse.
Prostate cancer (CaP) is a formidable public health problem in the US and in industrialized countries worldwide. Methods for primary prevention of CaP are unknown. As a result, early detection has become a mainstay of cancer control efforts. However, there is considerable controversy regarding the efficacy of screening in reducing disease-specific mortality. In light of this uncertainty, major medical organizations, including the National Cancer Institute, currently recommend that men discuss the pros and cons of CaP screening and make individualized screening decisions with their health care providers. However, because of constraints on time during medical encounters, it is not always feasible for providers to engage in in-depth discussions regarding the complexities of this issue. Therefore, interventions to promote informed decision-making (IDM) outside of clinical settings are needed.

In this study, we propose to: (1) develop an interactive computer-based decision aid (DA) to promote IDM for CaP screening; and (2) conduct a randomized controlled worksite trial to evaluate the impact the DA intervention on employed men's ability to make informed decisions regarding CaP. This work is designed to be responsive to recent calls for IDM interventions in community settings among diverse populations. If successful, our findings could validate the effectiveness of DAs to promote IDM for CaP and serve as a model for widespread dissemination, thus improving quality of care.
The invention provides a traditional Chinese medicine cataplasm for acupoint application therapy of chronic fatigue syndrome and a preparation method thereof. The traditional Chinese medicine cataplasm comprises non-woven fabric, an anti-sticking film and drug-containing paste. The drug-containing paste comprises magnet, radix astragali, pilose asiabell root, toasted polygala root, poria with hostwood, fruit of Chinese magnoliavine, fructus amomi, albizia bark, sodium carboxymethylcellulose, sodium polyacrylate, carbomer, glycerin, gelatin, peach gum, polyvinylpyrrolidone, sodium hydroxide, borneol, menthol, purified water and ethanol. The preparation method comprises the following steps of respectively extracting extract I, volatile oil and extract II, preparing a matrix, adding borneol, menthol, the extract I, the volatile oil and the extract II into the matrix, carrying out stirring to obtain a uniform mixture, and carrying out coating, slicing and packaging to obtain the cataplasm. The traditional Chinese medicine cataplasm has substantial curative effects on chronic fatigue syndrome and does not cause allergy easily. The preparation method has simple processes and can be operated easily.
BACKGROUND: Acute kidney injury (AKI) is common in septic patients and strongly associated with adverse outcomes. The pathophysiology of AKI in septic patients remains elusive, and detection of patients at risk of AKI or at risk of progression to severe and persistent AKI is critical for timely and adequate support measures, including mitigating further renal damage. Therefore, identification of biomarkers associated with septic-associated AKI that contribute to improve septic AKI is an area of intensive research.
METHODS: A total of 116 consecutive patients with sepsis were categorized into two groups (AKI and non-AKI) based on the occurrence of AKI within 24 h of admission to the intensive care unit (ICU). Serum levels of soluble TLR2 (sTLR2), as well as biomarkers such as interleukin(IL)-6, IL-22, IL-10, creatinine, urea, procalcitonin, hypersensitive C-reactive protein (hs-CRP), and D-Dimer (D2), were measured within 24 h after ICU admission. Demographic and clinical characteristics including sequential organ failure assessment (SOFA) scores and acute physiology and chronic health evaluation II (APACHE II) scores were recorded. Logistic regression analysis was conducted to identify potential predictive biomarkers. Receiver operating characteristic (ROC) curve analysis was employed to determine the optimal model for predicting septic-associated AKI.
RESULTS: Patients in the AKI group exhibited significantly higher serum concentrations of IL-6, IL-10, sTLR2, creatinine, urea, hs-CRP, procalcitonin, D2 and lower serum albumin concentrations as well as higher APACHE II scores compared to those in the non-AKI group. Logistic regression analysis revealed that APACHE II scores, log10-transformed sTLR2 concentration, creatinine and D2 concentration were valuable predictors of AKI among septic patients. ROC curves demonstrated that log10-transformed sTLR2 concentration exhibited comparable predictive value to creatinine in determining the incidence of sepsis-associated AKI. The model with variables of APACHE II score, Log10-transformed serum TLR2 concentration, creatinine and D2 concentration yielded the greatest area under the curve of 0.863.
CONCLUSION: Elevated levels of sTLR2 in early-stage of septic patients may serve as a promising novel biomarker for predicting sepsis-associated AKI.
This is a randomized, Phase 2/3 study of rociletinib versus erlotinib as a first-line treatment for patients with EGFR-mutant advanced/metastatic NSCLC whose tumors have EGFR-activating mutations. The study will consist of Phase 2 and Phase 3 parts which will use the same enrollment criteria and treatment assignment principles. Patients will be randomized 1:1 to erlotinib or rociletinib. The Phase 2 part is an open-label study. In the Phase 3 part, the sponsor will be blinded to the efficacy and safety results. The study will consist of a screening phase to establish study eligibility (including tumor genotype) and document baseline measurements, a treatment phase, in which patients will receive either rociletinib BID (twice a day) or erlotinib QD (once daily) to ascertain safety and efficacy until protocol-defined disease progression, and a follow-up phase, to monitor survival status and subsequent NSCLC cancer therapy. In the Phase 2 part only, patients initially randomized to erlotinib may be eligible to participate in an optional crossover phase to receive rociletinib if they demonstrate the T790M resistance mutation after radiographic progression on erlotinib treatment among other eligibility requirements. Patients eligible for this study must have EGFR-mutated NSCLC who have not been treated with an EGFR-directed therapy.Treatment with rociletinib or erlotinib is continuous. Each 28 day period of treatment will represent one cycle, with dosing initiated on Cycle 1 Day 1 (C1 D1).
Hypochondriasis is defined as a preoccupation with the fear of having a serious disease based on the person's misinterpretation of bodily symptoms (APA). For a long time hypochondriasis was seen as difficult to treat. Meanwhile effective psychological treatment for hypochondriasis exists. Psychotherapies using cognitive therapy (CT), cognitive behavioral therapy (CBT), exposure therapy (ET) or behavioral stress management approaches are effective in reducing symptoms of hypochondriasis. However, few studies compare different types of psychotherapy. In addition, in these studies numbers of participants were small, no differences between different treatments were found, and one third of the participants showed no satisfactory change. This study will compare the efficacy of CT and ET in a larger sample of 84 participants.

Participants in this randomized controlled trial (RCT) will first undergo baseline assessment. Then they will be randomly assigned to either CT, ET or a waiting list (WL), all conditions are for the duration of 12 weeks. CT includes psychoeducation, attention training, cognitive restructuring, behavioral experiments, imagery rescripting and relapse prevention. ET includes change of safety behavior, exposition (in sensu and in vivo), and relapse prevention. Both treatment trials contain the identical number of sessions. Treatment response will be assessed at week 12 and additionally one and three years after treatment. Participants of the WL will be assigned to CT or ET after the waiting period.
PROBLEM TO BE SOLVED: To obtain the subject composition, an antidemential agent composition, increased in stability to light, by formulating an antidemential agent with an organic acid. SOLUTION: This composition, an antidemential agent composition, is obtained by formulating (A) 1 pt.wt. of an antidemential agent (e.g. donepezil) with (B) pref. 0.2-2 pts.wt. of an organic acid (e.g. tosilic acid, mesilic acid, citric acid, salicylic acid). This composition is usable in a dosage form such as tablets, granules, powder, ointment or injection; for example, in the case of granules, this composition can be obtained by the following process: an antidemential agent is mixed with a vehicle such as lactose, mannitol or cornstarch followed by incorporation of a solution such as aqueous solution of a binder such as hydroxypropyl cellulose or polyvinylpyrrolidone, and the resulting blend is subjected to e.g. an extrusive granulator;  for ointment, this composition is usable in combination with an ointment base such as liquid paraffin, hydrogenated oil, squalane, higher alcohol or higher fatty acid.
The invention discloses a composition used for producing functional foods, health-care products and medicines. The composition used for producing the functional foods, the health-care products and the medicines is mainly prepared from the following raw materials in parts by weight: 42-75 parts of fungus polysaccharides, 10-20 parts of seaweed polysaccharides, 12-20 parts of plant polysaccharides, 18-25 part of plant powder, 49-73 parts of pollens, 30-45 parts of fruit powder, 30-45 parts of vegetable powder and 30-45 parts of grain powder. The composition is a natural active raw material prepared from the raw materials, including fungus polysaccharides, the seaweed polysaccharides, the plant polysaccharides, the plant powder, the pollens, the fruit powder, the vegetable powder, the grain powder and so on; and the preparation method of the composition comprises the following steps: carrying out pre-treating, carrying out fermenting, carrying out blending, and carrying out pelletizing. The raw materials utilized for preparing the composition are all natural excellent ingredients which are rich in nutrition and unique in flavor. The preparation method is simple and easy to perform, and the technological processes are easy to implement. The prepared products can be widely used as a natural active raw material for producing functional foods, health-care products the medicines.
Participants in this group will receive the same drugs used during the standard-of-care treatment for ambulatory spinal surgery. However, the drugs will be prescribed using a simple multimodal medication pre-formulated package for 7 days.
INTRODUCTION: Verbal fluency tasks are common in Alzheimer's disease (AD) assessments. Yet, standard valid response counts fail to reveal disease-specific semantic memory patterns. Here, we leveraged automated word-property analysis to capture neurocognitive markers of AD vis-à-vis behavioral variant frontotemporal dementia (bvFTD).
METHODS: Patients and healthy controls completed two fluency tasks. We counted valid responses and computed each word's frequency, granularity, neighborhood, length, familiarity, and imageability. These features were used for group-level discrimination, patient-level identification, and correlations with executive and neural (magnetic resonanance imaging [MRI], functional MRI [fMRI], electroencephalography [EEG]) patterns.
RESULTS: Valid responses revealed deficits in both disorders. Conversely, frequency, granularity, and neighborhood yielded robust group- and subject-level discrimination only in AD, also predicting executive outcomes. Disease-specific cortical thickness patterns were predicted by frequency in both disorders. Default-mode and salience network hypoconnectivity, and EEG beta hypoconnectivity, were predicted by frequency and granularity only in AD.
DISCUSSION: Word-property analysis of fluency can boost AD characterization and diagnosis.
HIGHLIGHTS: We report novel word-property analyses of verbal fluency in AD and bvFTD. Standard valid response counts captured deficits and brain patterns in both groups. Specific word properties (e.g., frequency, granularity) were altered only in AD. Such properties predicted cognitive and neural (MRI, fMRI, EEG) patterns in AD. Word-property analysis of fluency can boost AD characterization and diagnosis.
The present invention provides two synthetic tetrapeptides that have high binding affinity for human muscle nicotinic acetylcholine receptors (HmnAChR). Compositions for inhibiting contraction of muscle cells are also provided. The composition comprises an effective amount of one of the two peptides. Also provided are methods for inhibiting contraction of a muscle cell, the method comprising treating the muscle cell with an effective amount of the composition. Further provided are methods for inducing proliferation of epidermal cells, the methods comprising treating epidermal cells with an effective amount of a composition. The epidermal cells may be Human Epidermal Keratinocytes (HEK).
Participants with non-metastatic, treatment-naive Castration-Resistant Prostate Cancer (CRPC) with rapidly rising Prostate Specific Antigen (PSA) will be enrolled. ARN-509 will be administered at Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D), determined in Phase 1.